Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-GD2 antibody-drug conjugate M3554

An antibody-drug conjugate (ADC) composed of the humanized monoclonal antibody dinutuximab (ch14.18) directed against the tumor-associated antigen (TAA) disialoganglioside (GD2; GD-2) conjugated, via a cleavable beta-glucuronide linker, to the camptothecin analog and topoisomerase 1 inhibitor exatecan, with potential antineoplastic activity. Upon administration of anti-GD2 ADC M3554, dinutuximab targets and binds to GD2 expressed on tumor cells. Upon binding, internalization and linker cleavage, exatecan is released. Exatecan inhibits DNA topoisomerase 1 activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of GD2-expressing tumor cells. GD2 is overexpressed in certain tumor types including neuroblastoma, osteosarcoma, glioma and soft tissue sarcoma.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-GD2 ADC M3554
anti-GD2/exatecan ADC M3554
Code name:M 3554
M-3554
M3554
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search